ArticleBioengineering (Basel, Switzerland)2026
ICIsc: A Deep Learning Framework for Predicting Immune Checkpoint Inhibitor Response by Integrating scRNA-Seq and Protein Language Models.
Article in Bioengineering (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4 are widely used in the treatment of several cancers and have significantly improved survival outcomes in responsive patients. However, a substantial proportion of patients fail to benefit from these therapies, underscoring the urgent need for accurate prediction of ICI response. We propose a deep learning framework, ICIsc, to accurately predict ICI response by integrating single-cell RNA sequencing (scRNA-seq) data with protein large language models. Specifically, patient representations are constructed using transcriptomic profiles and immune-related gene set scores as latent embedding features, while drug representations are derived from amino acid sequences of ICI encoded by the Evolutionary Scale Modeling 2 (ESM2). For bulk data, ICIsc employs a bilinear attention module to fuse patient and drug embeddings for response prediction. For scRNA-seq data, ICIsc infers cell-cell interactions using a single-sample network (SSN) approach and applies GATv2 to model immune microenvironment heterogeneity at the single-cell level. Benchmark evaluations and independent validation demonstrate that ICIsc consistently outperforms baseline models and exhibits robust generalization performance. SHAP-based interpretability analysis further identifies key genes (e.g.,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.